IDEXX Laboratories, Inc. $IDXX Stock: Factory Mutual Insurance Co. Decreases Position

IDEXX Laboratories logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Factory Mutual Insurance Co. cut its IDEXX Laboratories stake by 9.8% in the third quarter, selling 4,470 shares and ending the period with 41,230 shares valued at about $21.5 million. Institutional investors overall own 87.84% of the company.
  • IDEXX beat third-quarter expectations, reporting adjusted EPS of $3.96 versus $3.71 expected and revenue of $1.21 billion, up 9.9% year over year. The company also raised its 2026 earnings and revenue outlook.
  • Soft veterinary-visit trends remain a demand challenge, though diagnostics growth has helped offset the weakness. Analysts’ consensus rating is “Moderate Buy,” with an average price target of $719.55.
  • Five stocks we like better than IDEXX Laboratories.

Factory Mutual Insurance Co. decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 9.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 41,230 shares of the company's stock after selling 4,470 shares during the period. Factory Mutual Insurance Co. owned about 0.05% of IDEXX Laboratories worth $21,530,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of IDXX. Bank of New York Mellon Corp purchased a new position in shares of IDEXX Laboratories in the second quarter valued at $628,223,000. Arrowstreet Capital Limited Partnership boosted its position in shares of IDEXX Laboratories by 52.4% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company's stock worth $471,335,000 after buying an additional 288,471 shares in the last quarter. International Assets Investment Management LLC boosted its position in shares of IDEXX Laboratories by 30,484.1% in the 3rd quarter. International Assets Investment Management LLC now owns 234,274 shares of the company's stock worth $122,336,000 after buying an additional 233,508 shares in the last quarter. Alyeska Investment Group L.P. boosted its position in shares of IDEXX Laboratories by 97.3% in the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company's stock worth $211,146,000 after buying an additional 197,808 shares in the last quarter. Finally, American Capital Management Inc. purchased a new stake in shares of IDEXX Laboratories in the 2nd quarter worth about $85,341,000. Institutional investors and hedge funds own 87.84% of the company's stock.

Key IDEXX Laboratories News

Here are the key news stories impacting IDEXX Laboratories this week:

  • Positive Sentiment: Third-quarter results beat expectations: IDEXX reported adjusted earnings of $3.96 per share versus $3.71 expected, while revenue rose about 10% year over year to $1.21 billion, above estimates. Recurring diagnostics sales to veterinarians were a key growth driver. IDXX Q3 Earnings & Revenues Surpass Estimates
  • Positive Sentiment: The company raised its full-year 2026 outlook, projecting EPS of $14.96–$15.16, above the $14.86 consensus, and revenue of $4.7–$4.8 billion, versus expectations of about $4.7 billion. The higher forecast reinforces optimism after the quarterly beat. IDEXX raises forecast
  • Positive Sentiment: Morgan Stanley maintained an Overweight/Buy view and raised its price target to $810, signaling further potential upside in the analyst’s assessment. Morgan Stanley stock recommendations
  • Positive Sentiment: A technical analysis report said IDXX moved above its 200-day moving average, a signal some investors interpret as supportive of a longer-term upward trend. IDXX crossed above the 200-day moving average
  • Negative Sentiment: Analysts noted that veterinary visits remain lackluster, creating a challenging demand backdrop. IDEXX’s results were strong despite this, but the company is relying on diagnostics growth to offset softer visit trends. UBS on IDEXX’s results and vet-visit backdrop

IDEXX Laboratories Price Performance

IDXX stock opened at $672.04 on Wednesday. The stock has a market capitalization of $52.94 billion, a price-to-earnings ratio of 45.38 and a beta of 1.55. The company has a quick ratio of 0.87, a current ratio of 1.19 and a debt-to-equity ratio of 0.16. IDEXX Laboratories, Inc. has a 52-week low of $500.61 and a 52-week high of $769.98. The stock's fifty day simple moving average is $538.81 and its 200-day simple moving average is $573.69.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Monday, November 2nd. The company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.71 by $0.25. The firm had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.19 billion. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The business's quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.22 earnings per share. Equities research analysts expect that IDEXX Laboratories, Inc. will post 15.05 EPS for the current year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the firm's stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director directly owned 9,568 shares of the company's stock, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.79% of the company's stock.

Analysts Set New Price Targets

IDXX has been the subject of several recent research reports. Citigroup raised their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a report on Wednesday, August 5th. Weiss Ratings upgraded shares of IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, October 8th. The Goldman Sachs Group started coverage on shares of IDEXX Laboratories in a report on Friday, October 16th. They issued a "buy" rating and a $740.00 price target on the stock. Barclays lowered their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 11th. Finally, Morgan Stanley increased their price target on shares of IDEXX Laboratories from $805.00 to $810.00 and gave the company an "overweight" rating in a research report on Tuesday. Seven equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $719.55.

View Our Latest Stock Analysis on IDXX

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX's companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.

Recommended Stories

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in IDEXX Laboratories Right Now?

Before you consider IDEXX Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.

While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines